CapsoVision (NASDAQ:CV) reported second-quarter revenue growth as sales of its CapsoCam Plus capsule endoscopy system increased, while the company advanced its artificial intelligence software rollout and development programs for colon and upper gastrointestinal applications.
Revenue for the second
CapsoVision (NASDAQ:CV) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
CapsoVision (NASDAQ:CV) reported steady first-quarter revenue and said it continues to advance artificial intelligence and capsule endoscopy programs aimed at expanding the use of its gastrointestinal imaging platform.
On the company’s first-quarter 2026 earnings call, President and Chief Executive
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Roth Capital Partners acted as joint book-running manager for the initial public offering of CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company focused on AI-powered capsule endoscopy solutions. CapsoVision offered 5,500,000 shares of common stock at $5.00 per share, with gross proceeds totaling approximately $27.5 million before deductions. The shares began trading on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol “CV.” The company also granted underwriters a 30-day option to purchase up to an additional 825,000 shares at the IPO price.
